Assyro AI

FDA Orange Book · active-ingredient family

Pentoxifylline

Pentoxifylline is approved as 1 brand and 10 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:TRENTAL · NDA 018631

1

Brand (NDA)

10

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet, extended release

ProductApplicantApplicationTEApproved
TRENTALRLDVALIDUS PHARMSNDA 018631Aug 30, 1984

Generic (ANDA) products (10)

ProductApplicantApplicationTEApproved
PENTOXIFYLLINEANI PHARMSANDA 075199Sep 03, 1999
PENTOXIFYLLINEIMPAX LABSANDA 075093Aug 10, 1999
PENTOXIFYLLINEAPOTEXANDA 075191ABJun 09, 1999
PENTOXIFYLLINEPLIVAANDA 074874May 25, 1999
PENTOXILUPSHER SMITH LABSANDA 074962Mar 31, 1999
PENTOXIFYLLINEANI PHARMSANDA 075107Sep 04, 1998
PENTOXIFYLLINEBAUSCHANDA 075028Jul 20, 1998
PENTOXIFYLLINEANI PHARMSANDA 074878ABJul 09, 1997
PENTOXIFYLLINEHERITAGEANDA 074877Jul 08, 1997
PENTOXIFYLLINERISINGANDA 074425ABJul 08, 1997

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Pentoxifylline — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.